Gilead Sciences Inc. (GILD) on Wednesday posted a third-quarter loss as a one-time charge related its acquisition of Corus Pharma Inc. offset higher sales of the company's drugs for HIV, the virus that causes AIDS.

The biotechnology company reported a net loss of $52.2 million, or 11 cents per share, compared with net income of $179.2 million, or 38 cents per share, a year earlier.